Muscle Coordination Rehabilitation Using Visual Guidance for Arm Weakness After Stroke
Tests a visually guided muscle coordination exercise for arm weakness in chronic stroke.
Plain-language title generated from the registry record
Registry title: Neuro-Intermuscular Coordination Enhancement (NICE) Rehabilitation Through Human-Machine Interaction in Chronic Stroke
Key facts
- Where
- Houston, United StatesSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 80 years old?
Source: NCT07531264, who can take part
Where in United States
- University of HoustonHouston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Houston
- Trial code
- NCT07531264
- Record updated
- 18 June 2026
- Original description
The objective of this study is to develop Neuro-Intermuscular Coordination Enhancement (NICE) rehabilitation, a novel neuromuscular control signal-guided strategy that visually guides stroke patients to individually activate motor modules through human-machine interaction. Ultimately, the development will lead to better clinical motor recovery, better quality of life, and lowered healthcare costs associated with the impairment.Read full original descriptionShow less
Neuro-Intermuscular Coordination Enhancement (NICE) Rehabilitation
The objective of this study is to develop Neuro-Intermuscular Coordination Enhancement (NICE) rehabilitation, a novel neuromuscular control signal-guided strategy that visually guides stroke patients to individually activate motor modules through human-machine interaction. Ultimately, the development will lead to better clinical motor recovery, better quality of life, and lowered healthcare costs associated with the impairment.
Inclusion: Hemiparetic chronic stroke survivors more than 6 months after stroke onset; Adults aged 21-80 years, including both female and male participants; Individuals with a single unilateral ischemic or hemorrhagic stroke; Individuals with Upper Extremity Fugl-Meyer Assessment score between 10 and 59 out of 66; Individuals who have not received botulinum toxin injections in the upper extremity within the past 3 months; Individuals without severe spasticity, defined as Modified Ashworth Scale score ≤3 at the elbow and shoulder; Healthy adults aged 21-80 years, including both female and male participants; Individuals with no known neurological or orthopedic injuries.
Exclusion: Individuals with an orthopedic disorder involving the upper limbs; Individuals with cognitive impairment sufficient to interfere with informed consent or successful completion of the protocol, assessed using the Montreal Cognitive Assessment or other IRB-approved screening procedures; Individuals whose stroke-affected arm has an intermuscular coordination pattern similarity score >0.80 relative to the non-affected arm; Individuals with known neurological disorders; Individuals with orthopedic injuries or conditions affecting upper-extremity movement; Individuals younger than 21 years of age or older than 80 years of age; Individuals younger than 21 years of age or older than 80 years of age; Individuals unable to produce voluntary upper-extremity muscle EMG activity; Individuals unable to provide informed consent.